The efficacy and safety comparation between Nucleoside (acid) analogue initial combination and monotherapy in the treatment of chronic hepatitis B for 144 weeks
10.3760/cma.j.issn.1003-9279.2014.02.002
- VernacularTitle:核苷(酸)类似物初始联合与单药治疗慢性乙型肝炎144周疗效和安全性比较
- Author:
Jie WANG
1
;
Junping SHI
;
Mengfei ZHU
;
Gongying CHEN
;
Jing LIU
;
Xiang ZHOU
Author Information
1. 310015,杭州师范大学附属医院
- Keywords:
Lamivudine;
Adefovir;
Entecavir;
Hepatitis B chronic;
Antiviral agents
- From:
Chinese Journal of Experimental and Clinical Virology
2014;28(2):82-84
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of lamivudine and adefovir combined with entecavir initial monotherapy in the treatment of chronic hepatitis B for 144 weeks.Methods Collected 120 patients with chronic hepatitis initial treatment,which adefovir + lamivudine (LAM + ADV) initial combination group and entecavir (ETV) monotherapy treatment group for 144 weeks,60 cases respectively.Results After treated for 144 weeks LAM + ADV group beneath the 300copy/ml detection rate,HBeAg serum conversion rate and conversion rates were higher than ETV treatment group (P ＜ 0.05),viral breakthrough rate was lower than the ETV group (P ＜ 0.05),HBV-DNA and HBsAg compared with baseline decline in absolute terms and ALT normalization had no statistical difference between the two groups (P ＞ 0.05),serum creatinine in two groups had no statistical difference,serum creatinine increased compared with baseline and differences were not statistically (P ＞ 0.05).Conclusions Lamivudine and adefovir in the initial joint sustained virologic response,reducing HBV-DNA,HBeAg seroconversion and combined response rate was superior to entecavir monotherapy,both are similar in terms of renal safety.
